FGF1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10719(FGF1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P10719(FGF1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

Fibroblast Growth Factor 1 (FGF1) is a member of the FGF family, which regulates cell proliferation, differentiation, survival, and migration. It binds to fibroblast growth factor receptors (FGFRs) and heparan sulfate proteoglycans to activate downstream signaling pathways like MAPK and PI3K-AKT, influencing tissue repair, angiogenesis, and metabolic processes. FGF1 antibodies are immunological tools designed to detect, quantify, or inhibit FGF1 in experimental and clinical settings.

Polyclonal or monoclonal FGF1 antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and ELISA to study FGF1 expression patterns in normal tissues, developmental stages, or diseases like cancer, where FGF1 overexpression is linked to tumor growth and metastasis. Researchers also employ neutralizing FGF1 antibodies to block its activity, elucidating its functional roles in angiogenesis, wound healing, and metabolic regulation.

In therapeutic contexts, FGF1 antibodies are explored for targeting FGF1-driven pathologies, including diabetic complications, cardiovascular diseases, and inflammatory disorders. Specificity validation (e.g., knockout controls) ensures minimal cross-reactivity with other FGF family members. As FGF1’s pleiotropic roles span both physiological repair and pathological signaling, its antibodies remain critical for dissecting molecular mechanisms and advancing biomarker or drug development.